CHICAGO – Blue Cross Blue Shield Association (BCBSA) announced a new web-based platform that provides health care decision-makers easy access to impartial medical evidence reviews for devices, diagnostics and pharmaceuticals.
The platform Evidence Street™ was created to make BCBSA’s evidence review process of medical technologies and therapies more transparent, efficient and comprehensive. BCBSA collects and analyzes available peer-reviewed evidence on devices, diagnostics and pharmaceuticals, then synthesizes that data and ascertains if the evidence is sufficient or insufficient to determine the effect on health outcomes.
By developing an online platform, health care product manufacturers are able to monitor when BCBSA is reviewing particular medical categories and are able to easily submit their peer-reviewed evidence for consideration during the review process. In addition, those subscribers who submit evidence will receive a customized report providing feedback about any relevant gaps in the findings from BCBSA.
Reviews are subsequently published on the Evidence Street website, which is accessible to Blue Cross and Blue Shield (BCBS) companies and subscribing health care device, diagnostic and pharmaceutical manufacturers. Medical societies, health care associations and academic medical research centers may also subscribe to the service.
“Today, as medical technology, treatment protocols and new discoveries accelerate and continue to evolve, Evidence Street provides an efficient platform to facilitate collaborative exchange of information between health care decision makers about the state of the evidence to inform health care decisions,” said Dr. Trent Haywood, senior vice president and chief medical officer for BCBSA. “Blue Cross and Blue Shield companies have long been committed to improving population health outcomes, and one of the most important ways we do that is by determining if current use of devices, diagnostics and pharmaceuticals is rooted in clinical evidence.”
BCBSA, which will provide about 460 medical reviews a year, does not determine whether each of the 36 Blue Cross and Blue Shield companies nationwide cover a medical technology. However, it provides BCBS companies with evidence opinions they often use as an input into those decisions.
Evidence Street builds on BCBSA’s history and commitment to evidence-based medicine and technology assessment. BCBSA pioneered the development of scientific criteria for assessing medical technologies through objective, comprehensive reviews of clinical evidence with a mission to provide health care decision-makers with rigorous and credible assessments from available evidence.
"Evidence Street is a destination where the market meets the evidence," Haywood added. “Our goal is to create clarity, efficiency and transparency for health care decision-makers regarding the current state of the evidence.”
About Evidence Street® (“Site”) Disclaimer
Evidence submitted to BCBSA via the Site is considered in the same impartial manner as other evidence provided manually by Subscribers, non-Subscribers, and other sources. Subscription or use of this Site will not enhance review of the submitted evidence or influence BCBSA’s impartial evaluation of all relevant evidence from all appropriate sources.
This Site and BCBSA do not determine medical policy, provide health insurance benefits information, or adjudicate coverage claims for any Blue Plan; do not provide medical, legal, or financial advice; and are not intended for consumer use.
Each local Blue Plan, as an independent entity, determines its own medical policies and benefits, adjudicates its own members’ claims, and may accept or reject information on this Site in its own discretion.